Ovid Therapeutics, Inc. is expanding its research and development efforts beyond its historical focus on seizure disorders and into areas such as psychiatric disorders and pain, the company highlighted during its third quarter sales and earnings call, building from the library of KCC2-targeting drugs that it acquired from AstraZeneca PLC after selling its interest in soticlestat back to Takeda Pharmaceutical Co. Ltd.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?